natgillin/translations-raw huggingface dataset:
Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro transdermal patch are nausea, vomiting, application site reactions, somnolence, dizziness and headache.
Neželeni učinki, o katerih so poročali pri več kot 10 % bolnikov, zdravljenih s transdermalnim obližem zdravila Neupro, so navzea, bruhanje, reakcije na mestu aplikacije, somnolenca, omotica in glavobol.
On the first day of treatment the patient starts with Neupro 2 mg/24 h. During the second week, the patient takes Neupro 4 mg/24 h. During the third week, he or she takes Neupro 6 mg/24 h and during the fourth week Neupro 8 mg/24 h. The packages are marked with “Week 1 (2, 3 or 4)”.
Prvi dan zdravljenja bolnik začne z obližem zdravila Neupro 2 mg/24 h. V drugem tednu uporablja zdravilo Neupro 4 mg/24 h. Tretji teden uporablja zdravilo Neupro 6 mg/24 h, četrti teden pa zdravilo Neupro 8 mg/24 h. Pakiranja so označena z nalepko “1.
Where to stick the patch Put the sticky side of the patch onto clean, dry, healthy skin on the following areas as shown in grey on the pictures opposite:
Kam namestiti obliž Lepljivo stran obliža namestite na čisto, suho, zdravo kožo na spodaj navedena mesta, kot je prikazano s sivimi predeli na sliki nasproti:
Boxes containing 7, 14, 28, 30 or 84 (multipack containing 3 packs of 28) patches, which are individually sealed in sachets.
Škatle, ki vsebujejo 7, 14, 28, 30 ali 84 (večkratno pakiranje vsebuje 3 pakiranja po 28) transdermalnih obližev, posamezno pakiranih v zaščitne vrečke.
Palpitationse, atrial fibrillatione, supraventricular tachycardiae
Srčne bolezni palpitacije atrijska fibrilacija supraventrikularna tahikardija
Neupro is for transdermal use.
Zdravilo Neupro je za transdermalno uporabo.
Adverse drug reactions (ADRs) reported in more than 10% of patients treated with Neupro are nausea, application site reactions, asthenic conditions and headache.
Neželeni učinki, o katerih so poročali pri več kot 10 % bolnikov, zdravljenih s transdermalnim obližem zdravila Neupro, so navzea, reakcije na mestu aplikacije, astenična stanja in glavobol.
The box contains 7, 14, 28, 30 or 84 (multipack containing 3 packs of 28) transdermal patches, individually sealed in sachets.
Škatla vsebuje 7, 14, 28, 30 ali 84 (večkratno pakiranje vsebuje 3 pakiranja po 28) transdermalnih obližev, posamezno pakiranih v zaščitne vrečke.
hypersexuality, libido increased), confusional state, disorientationd, agitationd
hiperseksualnostjo, povečanim libidom), zmedenost, dezorientiranost d,
Chemin du Foriest B-1420 Braine l'Alleud Belgium
B-1420 Braine l'Alleud
Palpitationse, atrial fibrillatione, supraventricular tachycardia e
atrijska fibrilacija e, supraventrikularna tahikardija e
What Neupro contains
Kaj vsebuje zdravilo Neupro
The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of Neupro in 7.2% of subjects.
Večina reakcij na mestu aplikacije je bila blagih ali zmernih, omejenih na mesto aplikacije, zdravljenje z zdravilom Neupro pa so zaradi njih prekinili le pri 7,2 % vseh bolnikov, ki so prejemali zdravilo Neupro.
How to use Neupro
Kako uporabljati zdravilo Neupro
• For doses higher than 8 mg/24 h (doses prescribed by your doctor above the available strengths),
• Za odmerke, večje kot 8 mg/24 h (odmerki, ki jih je predpisal zdravnik, in so večji od razpoložljivih jakosti) je treba uporabiti več obližev za doseg končnega odmerka.
The patch should be applied at approximately the same time every day.
Zdravilo Neupro namestimo enkrat na dan. Obliž je treba namestiti vsak dan ob približno istem času.
In trials where the application sites were rotated as reflected in the instructions provided in SmPC and package leaflet, 35.7% of 830 patients using the Neupro transdermal patch, experienced application site reactions.
Pri preskušanjih, v katerih so mesto aplikacije spreminjali po navodilih iz povzetka glavnih značilnosti zdravila in navodila za uporabo, so se reakcije na mestu aplikacije pojavile pri 35,7 % od 830 bolnikov, ki so uporabljali transdermalni obliž zdravila Neupro.
At the beginning of the fourth week, you should take Neupro 8 mg (package marked with “Week 4”).
Na začetku četrtega tedna zdravljenja uporabite zdravilo Neupro 8 mg (pakiranje označeno z nalepko “4.
Neupro should be discontinued gradually.
Zdravljenje z obližem zdravila Neupro je treba prekiniti postopno.
At the end of maintenance, the mean UPDRS part III score had improved by 7.0 points in rotigotine-treated patients (baseline 29.6), and by 3.9 points in the placebogroup (baseline 32.0).
Na koncu vzdrževalnega zdravljenja se je pri bolnikih, zdravljenih z rotigotinom, srednja vrednost rezultatov UPDRS III. del izboljšala za 7,0 točk (izhodiščna vrednost 29.6), pri bolnikih, ki so prejemali placebo, pa za 3,9 točke (izhodiščna vrednost 32,0).
• movements you cannot control related to Parkinson's disease (dyskinesia)
• nekontolirani gibi, povezani s Parkinsonovo boleznijo (diskinezija)
Self adhesive matrix layer
Samolepilna matriksna plast:
In trials where the application sites were rotated as reflected in the instructions provided in the SmPC and package leaflet, 34.2% of 748 patients using Neupro, experienced application site reactions.
Pri preskušanjih, v katerih so mesto aplikacije spreminjali po navodilih iz povzetka glavnih značilnosti zdravila in navodila za uporabo, so se reakcije na mestu aplikacije pojavile pri 34,2 % od 748 bolnikov, ki so uporabljali transdermalni obliž zdravila Neupro.
Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ‘on-off' fluctuations).
Uporablja se kot monoterapija (brez L-dope) ali v kombinaciji z L-dopo, v poteku bolezni, do poznih faz, ko učinek L-dope popušča ali postane neustrezen ter ko se pojavijo nihanja terapevtskega učinka (ob koncu odmerjanja ali nihanja »vklop-izklop«).
At the beginning of the third week, you should take Neupro 6 mg (package marked with “Week 3”).
Na začetku tretjega tedna zdravljenja uporabite zdravilo Neupro 6 mg (pakiranje označeno z nalepko“3.
The daily dose should be reduced in steps of 1 mg/24 h with a dose reduction preferably every other day, until complete withdrawal of Neupro (see section 4.4).
Dnevni odmerek zmanjšujemo v korakih po 1 mg/24 h, po možnosti vsak drugi dan, do popolne odtegnitve zdravila Neupro (glejte poglavje 4.4).
Neupro can cause unusual urges or cravings which you cannot resist such as the impulse, drive or temptation to do things that could harm yourself or others.
Zdravilo Neupro lahko povzroči nenavadne težnje ali želje, ki se jim ne morete upreti in bi lahko škodovale vam ali drugim.
paranoia e, confusional state e, psychotic disorder e, delusione, deliriume
psihotične motnje e, blodnje e, delirij e
On the first day of treatment, start with Neupro 2 mg (package marked “Week 1”), and use one Neupro 2 mg transdermal patch daily.
Prvi dan zdravljenja začnite z zdravilom Neupro 2 mg (pakiranje označeno z nalepko “1.
For example the daily dose of 10 mg may be reached by applying one patch of 6 mg/24 h and one patch of 4 mg/24 h.
Na primer, dnevni odmerek 10 mg lahko dosežete tako, da uporabite en obliž z odmerkom 6 mg/24 h in enega z odmerkom 4 mg/24 h.
How to use the Neupro patches
Kako uporabljati Neupro obliže
Neupro is a patch that is put on the skin.
Zdravilo Neupro je obliž, ki ga prilepite na kožo.
The daily dose should be reduced in steps of 2 mg/24 h with a dose reduction preferably every other day, until complete withdrawal of Neupro (see section 4.4).
Dnevni odmerek zmanjšujemo po 2 mg/24 h, po možnosti vsak drugi dan, do popolne odtegnitve zdravila Neupro (glejte poglavje 4.4).
Adverse reactions of increased creatine phosphokinase (CPK) were observed with rotigotine in clinical studies conducted in Japan.
Pri kliničnih študijah, izvedenih na Japonskem, so opazili neželene učinke zvišane kreatin fsofokinaze (CPK).
You must take your Neupro patch off just before undergoing magnetic resonance imaging (MRI) or cardioversion to avoid skin burns because the patch contains aluminium.
Da se izognete opeklinam na koži, morate obliž zdravila Neupro morate odstraniti tik pred magnetnoresonančnim slikanjem ali kardioverzijo, saj obliž vsebuje aluminij.
Tell your doctor if you notice any changes in behaviour, thinking or both, that are listed below.
Spremembe v vedenju in nenormalno mišljenje Povejte zdravniku, če opazite kakršnekoli spremembe v vedenju, mišljenju ali obeh, kot je navedeno spodaj.
Erythemae, hyperhidrosise, pruritus generalisede, skin irritatione, dermatitis contacte, rash generalisede
Bolezni kože in podkožja eritem, hiperhidroza, pruritus razširjen pruritus, draženje kože, kontaktni dermatitis razširjen izpuščaj
AST, ALT, GGT), weight increased e, heart rate increased e, CPK increased d,e
(vključno z AST, ALT, γ GT), povečanje telesne mase e, pospešeno bitje srca e, zvišan CPK
Psychotic disorder, obsessivecompulsive disorder, aggressive behaviour/ aggressionb, delusiond, deliriumd
obsesivno kompulzivna motnja, agitiranost d nasilno vedenje/ agresivnost b, dezorientiranost d dopaminski disregulacijski sindrom c,
• sedating medicines such as benzodiazepines or medicines used to treat mental illness or depression.
Pred uporabo zdravila Neupro se pogovorite z zdravnikom, če jemljete • sedative, kot so benzodiazepini ali zdravila za zdravljenje duševnih bolezni ali depresije.
Neupro 2 mg/24 h Neupro 4 mg/24 h Neupro 6 mg/24 h Neupro 8 mg/24 h Transdermal patch
Neupro 2 mg/24 h Neupro 4 mg/24 h Neupro 6 mg/24 h Neupro 8 mg/24 h transdermalni obliž rotigotin
Nausea, vomiting Constipation, dry mouth, dyspepsia
Bolezni prebavil navzea, bruhanje zaprtje, suha usta, dispepsija bolečine v trebuhu driskac
hallucination, hallucination visual, hallucination auditory, illusion), insomnia, sleep disorder, nightmare, abnormal dreams, impulsecontrol disorders a,d
(vključno s halucinacijami, vizualnimi halucinacijami, zvočnimi halucinacijami, iluzijami), nespečnost, motnje spanja, nočne more, nenavadne sanje, motnje pri kontroli dražljajev a,d
sodium metabisulphite (E223), ascorbyl palmitate (E304) and DL-α-tocopherol (E307).
(E223), askorbilpalmitat (E304) in DL-α-tokoferol (E307)
The outside is tan-coloured and is imprinted with Neupro 1 mg/24 h or 3 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Neupro 1 mg/24 h ali 3 mg/24 h.
Side effects when using Neupro for Restless Legs Syndrome Tell your doctor or pharmacist if you notice any of the following side effects:
Neželeni učinki pri uporabi zdravila Neupro za zdravljenje sindroma nemirnih nog Če se pojavijo naslednji neželeni učinki, se posvetujte z zdravnikom ali farmacevtom:
Neupro may make you feel very sleepy and you may fall asleep very suddenly.
Vpliv na sposobnost upravljanja vozil in strojev Zaradi zdravila Neupro ste lahko zelo zaspani in lahko povsem nenadno zaspite.
At the beginning of the second week, you should take Neupro 4 mg (package marked with “Week 2”).
Na začetku drugega tedna zdravljenja uporabite zdravilo Neupro 4 mg (pakiranje označeno z nalepko “2.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathologic gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including rotigotine.
Bolniki in negovalci se morajo zavedati, da se lahko pri bolnikih, zdravljenih z agonisti dopamina, vključno z rotigotinom, pojavijo vedenjski simptomi motenj kontrole dražljajev kot so patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno zapravljanje ali nakupovanje, prenajedanje in kompulzivno prehranjevanje.
Vision blurrede, visual impairmente, photopsiae
Očesne bolezni zamegljen vid okvara vida, fotopsija
• Poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate, povidoneK90, sodium metabisulphite (E223), ascorbyl palmitate (E304) and DL-α-tocopherol (E307).
• poli(dimetilsiloksan, trimetilsililsilikat)-kopolimerizat, povidon K90, natrijev metabisulfit (E223), askorbilpalmitat (E304) in DL-α-tokoferol (E307).
• Thigh or hip.
• Stegno ali kolk.
What Neupro is Neupro contains the active substance rotigotine.
Zdravilo Neupro vsebuje učinkovino rotigotin.
syncope, syncope vasovagal, loss of consciousness), dyskinesiae, dizziness posturale, lethargye, convulsione
(vključno s sinkopo, vazovagalno sinkopo, izgubo zavesti) diskinezija, posturalna omotica, letargija konvulzija sindrom padajoče glave c
The outside is tan-coloured and is imprinted with Neupro 4 mg/24 h, Neupro 6 mg/24 h or Neupro 8 mg/ 24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Neupro 4 mg/24 h, Neupro 6 mg/24 h ali Neupro 8 mg/24 h.
Neupro was not investigated in patients with severe hepatic impairment.
Pri bolnikih s hudo jetrno okvaro zdravila Neupro niso raziskovali.
Do not breast-feed during treatment with Neupro.
Ne dojite med zdravljenjem z zdravilom Neupro, saj lahkorotigotin prehaja v mleko in učinkuje na otroka.
This is because rotigotine may pass into your breast milk and affect your baby.
Ne dojite med zdravljenjem z zdravilom Neupro, saj lahko rotigotin prehaja v mleko in učinkuje na otroka.
7 transdermal patches of Neupro 8 mg/24 h
7 transdermalnih obližev Neupro 8 mg/24 h
Neupro may cause other behaviours and abnormal thinking.
Zdravilo Neupro lahko povzroči tudi druge spremembe vedenja ali razmišljanja.
pathological gambling, stereotypy/ punding, binge eating/eating disorder b, compulsive shopping c)
(vključno s patološkim hazardiranjem, ponavljanjem nesmiselnih dejanj, prenajedanjem/ motnjami prehranjevanja b kompulzivnim nakupovanjemc)
Poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate, Povidone K90, sodium metabisulphite (E223), ascorbyl palmitate (E304) and
poli(dimetilsiloksan, trimetilsililsilikat)-kopolimerizat, povidon K90, natrijev metabisulfit (E223), askorbilpalmitat (E304) in
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h'.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h ali 8 mg/24 h'.
7 transdermal patches of Neupro 4 mg/24 h
7 transdermalnih obližev Neupro 4 mg/24 h
Neupro 8 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 8 mg/24 h'.
Neupro 8 mg/24 h transdermalni obliž Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 8 mg/24 h'.
Each patch of 30 cm2 contains 13.5 mg of rotigotine.
En obliž s površino 30 cm2 vsebuje 13,5 mg rotigotina.
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Neupro.
Pred začetkom uporabe zdravila Neupro se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, saj:
Each patch of 10 cm contains 4.5 mg of rotigotine.
Vsak obliž s površino 10 cm vsebuje 4,5 mg rotigotina.
7 transdermal patches of Neupro 6 mg/24 h
7 transdermalnih obližev Neupro 6 mg/24 h
Each patch of 40 cm2 contains 18.0 mg of rotigotine.
En obliž s površino 40 cm2 vsebuje 18,0 mg rotigotina.
erythema, pruritus, irritation, rash, dermatitis, vesicles, pain, eczema, inflammation, swelling, discolouration, papules, exfoliation, urticaria, hypersensitivity)
(vključno z eritemom, pruritusom, draženjem, izpuščajem , dermatitisom, mehurji, bolečino, ekcemom, vnetjem, oteklino, razbarvanjem, papulami, lupljenjem, koprivnico, preobčutljivostjo)
Hiccups e
fotopsija e
Poly(dimethylsiloxane, trimethylsilyl silicate)-copolymerisate, Povidone K90,
• poli(dimetilsiloksan, trimetilsililsilikat)-kopolimerizat, povidon K90, natrijev metabisulfit
Each patch of 5 cm2 contains 2.25 mg of rotigotine.
En obliž s površino 5 cm2 vsebuje 2,25 mg rotigotina.
Neupro 1 mg/24 h transdermal patch EU/1/05/331/038
Neupro 1 mg/24 h transdermalni obliž EU/1/05/331/038
The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 2 mg/24 h'.
Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 2 mg/24 h'.
Each patch of 5 cm contains 2.25 mg of rotigotine.
Vsak obliž s površino 5 cm vsebuje 2,25 mg rotigotina.
Neupro 6 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 6 mg/24 h'.
Neupro 6 mg/24 h transdermalni obliž Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 6 mg/24 h'.
The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h ali 8 mg/24 h.
h may be reached by applying one patch of 6 mg/24 h and one patch of 4 mg/24 h.
dnevni odmerek 10 mg se lahko doseže z uporabo enega obliža jakosti 6 mg/24 h in enega obliža jakosti 4 mg/24 h.
The backing layer of Neupro contains aluminium.
Zdravilo Neupro vsebuje natrijev metabisulfit.
Neupro 4 mg/24 h transdermal patch The outside of the backing layer is tan-coloured and imprinted with ‘Neupro 4 mg/24 h'.
Neupro 4 mg/24 h transdermalni obliž Zunanja stran oporne plasti je rumenorjave barve, z natisnjenim napisom ‘Neupro 4 mg/24 h'.
Neupro 6 mg/24 h transdermal patch EU/1/05/331/007
Neupro 6 mg/24 h transdermalni obliž EU/1/05/331/007
• Do not cut the Neupro patches into pieces.
• Obliža zdravila Neupro ne razrežite na dele.
• 4 mg/24 h: Each patch releases 4 mg of rotigotine per 24 hours.
• 4 mg/24 h: Vsak obliž sprosti 4 mg rotigotina v 24 urah.
Sleep attacks/sudden onset of sleep, sexual desire disordersa (incl.
Psihiatrične motnje napadi spanca/nenaden spanec, motnje spolnega poželenja a
Neupro 3 mg/24 h transdermal patch EU/1/05/331/047
Neupro 3 mg/24 h transdermalni obliž EU/1/05/331/047
The outside is tan-coloured and is imprinted with Neupro 2 mg/24 h.
Zunanja stran je rumenorjave barve, z natisnjenim napisom Neupro 2 mg/24 h.
Neupro 4 mg/24 h transdermal patch EU/1/05/331/004
Neupro 4 mg/24 h transdermalni obliž EU/1/05/331/004
Neupro 8 mg/24 h transdermal patch EU/1/05/331/010
Neupro 8 mg/24 h transdermalni obliž EU/1/05/331/010
Each patch releases 6 mg of rotigotine per 24 hours.
Vsak obliž sprosti 6 mg rotigotina v 24 urah.
AST, ALT, GGT), weight increased, heart rate increased, CPK increasedd
Neznana telesne mase, pospešeno bitje srca, zvišan CPK
erythema, pruritus, irritation, rash, dermatitis, vesicles, pain, eczema, inflammation,
(vključno z eritemom, pruritusom, draženjem, izpuščajem, dermatitisom, mehurji, bolečino, ekcemom,
EU/1/05/331/047 [7 transdermal patches] EU/1/05/331/049 [28 transdermal patches] EU/1/05/331/050 [30 transdermal patches] EU/1/05/331/058 [14 transdermal patches]
EU/1/05/331/047 [7 transdermalnih obližev] EU/1/05/331/049 [28 transdermalnih obližev] EU/1/05/331/050 [30 transdermalnih obližev] EU/1/05/331/058 [14 transdermalnih obližev]
Neupro 4 mg/24 h transdermal patch Each patch releases 4 mg of rotigotine per 24 hours.
Neupro 4 mg/24 h transdermalni obliž En obliž sprosti 4 mg rotigotina v 24 urah.
Disturbances in consciousness NEC
Bolezni živčevja glavobol somnolenca omotica e, motnje zavesti NEC
EU/1/05/331/038 [7 transdermal patches] EU/1/05/331/040 [28 transdermal patches] EU/1/05/331/041 [30 transdermal patches] EU/1/05/331/056 [14 transdermal patches]
EU/1/05/331/038 [7 transdermalnih obližev] EU/1/05/331/040 [28 transdermalnih obližev] EU/1/05/331/041 [30 transdermalnih obližev] EU/1/05/331/056 [14 transdermalnih obližev]
EU/1/05/331/010 [7 transdermal patches] EU/1/05/331/011 [28 transdermal patches] EU/1/05/331/033 [30 transdermal patches] EU/1/05/331/061 [14 transdermal patches]
EU/1/05/331/010 [7 transdermalnih obližev] EU/1/05/331/011 [28 transdermalnih obližev] EU/1/05/331/033 [30 transdermalnih obližev] EU/1/05/331/061 [14 transdermalnih obližev]
syncope, syncope vasovagal, loss of consciousness), dyskinesia, dizziness postural, lethargy
(vključno s sinkopo, vazovagalno sinkopo, izgubo zavesti) diskinezija a,
Warnings and precautions Talk to your doctor or pharmacist before using Neupro.
Pred začetkom uporabe zdravila Neupro se posvetujte z zdravnikom ali farmacevtom, saj:
EU/1/05/331/004 [7 transdermal patches] EU/1/05/331/005 [28 transdermal patches] EU/1/05/331/021 [30 transdermal patches] EU/1/05/331/059 [14 transdermal patches]
EU/1/05/331/004 [7 transdermalnih obližev] EU/1/05/331/005 [28 transdermalnih obližev] EU/1/05/331/021 [30 transdermalnih obližev] EU/1/05/331/059 [14 transdermalnih obližev]
Irritability, oedema peripheral swelling, discolouration, papules, exfoliation, urticaria, hypersensitivity), asthenic conditionsa (incl.
Neznana vnetjem, oteklino, razbarvanjem, papulami, lupljenjem, koprivnico, preobčutljivostjo ), astenična stanja a
Neupro 1 mg/24 h transdermal patch rotigotine
Neupro 1 mg/24 h transdermalni obliž rotigotin
EU/1/05/331/001 [7 transdermal patches] EU/1/05/331/002 [28 transdermal patches] EU/1/05/331/015 [30 transdermal patches] EU/1/05/331/057 [14 transdermal patches]
EU/1/05/331/001 [7 transdermalnih obližev] EU/1/05/331/002 [28 transdermalnih obližev] EU/1/05/331/015 [30 transdermalnih obližev] EU/1/05/331/057 [14 transdermalnih obližev]
EU/1/05/331/007 [7 transdermal patches] EU/1/05/331/008 [28 transdermal patches] EU/1/05/331/027 [30 transdermal patches] EU/1/05/331/060 [14 transdermal patches]
EU/1/05/331/007 [7 transdermalnih obližev] EU/1/05/331/008 [28 transdermalnih obližev] EU/1/05/331/027 [30 transdermalnih obližev] EU/1/05/331/060 [14 transdermalnih obližev]
Neupro 8 mg/24 h transdermal patch rotigotine
Neupro 8 mg/24 h transdermalni obliž rotigotin
• From the second week, your daily dose may be increased by 1 mg each week until you get to the right maintenance dose for you.
• Od drugega tedna dalje se vam lahko dnevni odmerek po zdravnikovih navodilih zvišuje po 1 mg vsak teden, dokler se ne bo dosegel za vas ustrezen vzdrževalni odmerek.
Neupro 1 mg/24 h transdermal patch Neupro 3 mg/24 h transdermal patch
Neupro 1 mg/24 h transdermalni obliž Neupro 3 mg/24 h transdermalni obliž rotigotin
For most patients with advanced-stage Parkinson's disease the right dose is reached within 3 to 7 weeks, at doses of 8 mg per day up to a maximum dose of 16 mg per day.
Večina bolnikov v napredovali fazi Parkinsonove bolezni doseže ustrezni odmerek v 3 do 7 tednih, pri odmerkih od 8 mg na dan do največjega odmerka 16 mg na dan. Za odmerke, večje od 8 mg/24 h (odmerke, ki jih je predpisal zdravnik in so večji od razpoložljivih jakosti), je treba uporabiti več obližev za doseg končnega odmerka.
EU/1/05/331/018 [84 transdermal patches (3 packs of 28)]
EU/1/05/331/018 [84 transdermalnih obližev (3 pakiranja po 28)]
What Neupro is used for
Zakaj se uporablja zdravilo Neupro
Neupro 1 mg/24 h transdermal patch Each patch releases 1 mg of rotigotine per 24 hours.
KAKOVOSTNA IN KOLIČINSKA SESTAVA Neupro 1 mg/24 h transdermalni obliž En obliž sprosti 1 mg rotigotina v 24 urah.
EU/1/05/331/036 [84 transdermal patches (3 packs of 28)]
EU/1/05/331/036 [84 transdermalnih obližev (3 pakiranja po 28)]
Neupro 3 mg/24 h transdermal patch rotigotine
Neupro 3 mg/24 h transdermalni obliž rotigotin
If you are treated with Neupro and levodopa at the same time, some side effects may get more serious.
Če se sočasno zdravite z zdravilom Neupro in levodopo, lahko nekateri neželeni učinki postanejo resnejši, na primer videnje ali slišanje stvari, ki niso resnične (halucinacije), nekontrolirani gibi,
Neupro 2 mg/24 h transdermal patch rotigotine
Neupro 2 mg/24 h transdermalni obliž rotigotin
Neupro 6 mg/24 h transdermal patch rotigotine
Neupro 6 mg/24 h transdermalni obliž rotigotin
Dizzinesse, disturbances in consciousness NECe (incl.
Bolezni živčevja somnolenca, omotica, glavobol motnje zavesti NEC
To avoid skin burns, Neupro should be removed if the patient has to undergo magnetic resonance imaging (MRI) or cardioversion.
Če je treba pri bolniku opraviti magnetnoresonančno slikanje (MRI) ali kardioverzijo, obliž zdravila Neupro odstranimo, da preprečimo opekline kože.
Convulsion Dropped head syndrome c
blodnja d, delirij d dopaminski disregulacijski sindrom c